{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T06:52:51Z","timestamp":1722408771935},"reference-count":0,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":14461,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1976,6]]},"abstract":"<jats:p>An ascending series of single doses of the narcotic antagonist naltrexone, ranging from 20 to 160 mg, was administered to 8 abstinent former addicts in order to assess agonistic activity and any toxic side effects. There was tittle alteration of normal body function. Signijicant, but small, changes in sublingual temperature (0.4\u00b0 F decrease), and diastolic blood pressure (1.7 mm Hg increase) were induced. Among the battery of tests assessing behavioral or mood\u2010feeling variables, only 2 showed significant between\u2010condition effects: facilitated performance on the Cross\u2010out Test (attention and perception), and a dose\u2010related decrease in Morphine\u2010Benzedrine Group (MBG) scores of the Addiction Research Center 1nventory (ARCI) (mild euphoria). On the whole, subjects had few subjective reactions or unpleasant side effects. Naltrexone appears to be a safe, nontoxic medication in the dosage range examined.<\/jats:p>","DOI":"10.1002\/cpt1976196773","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:45:01Z","timestamp":1451958301000},"page":"773-776","source":"Crossref","is-referenced-by-count":37,"title":["Naltrexone: Physiological and psychological effects of single doses"],"prefix":"10.1111","volume":"19","author":[{"given":"Ellen R.","family":"Gritz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul M.","family":"Shiffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray E.","family":"Jarvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. C.","family":"Charuvastra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1976196773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt1976196773","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt1976196773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:35:27Z","timestamp":1699364127000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt1976196773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1976,6]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1976,6]]}},"alternative-id":["10.1002\/cpt1976196773"],"URL":"https:\/\/doi.org\/10.1002\/cpt1976196773","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1976,6]]}}}